Effects of platelet transfusion on post cardiopulmonary bypass bleeding

S Premaratne1, A M Razzuk, D R Premaratne

  • 1Department of Veterans Affairs, Hunter Holmes McGuire Veterans Administration Medical Center, and Department of Internal Medicine, Medical College of Virginia, Richmond 23249, USA.

Japanese Heart Journal
|November 6, 2001
PubMed

A common complication of cardiopulmonary bypass (CPB) surgery is post-operative bleeding that may result in re-exploration. Bleeding is often due to the coagulopathy that follows the procedure, rather than the surgical technique. Etiology of this coagulopathy has been attributed to platelet dysfunction. We reviewed the medical records of 592 patients who had undergone CPB surgery between 1992 and 1994. Bleeding times (both pre and post operative) in treated (those who received platelets) and untreated patients were recorded where available. Both groups showed a rise in bleeding time (295 sec versus 192 sec, respectively, p<0.001). However, the treated group had a greater increase in the bleeding time compared to the un-treated (p<0.05). The result was the same when we compared 2 subgroups with similar pre-operative bleeding times. When the treated group was subdivided into those who received >10 units of platelets and those who received <10 units, there was no significant difference in the increase in their bleeding times (p>0.1). Administration of platelets did not improve bleeding time abnormalities induced by CPB. Both treated and untreated groups had a significant rise in their bleeding times, irrespective of the amount of platelets administered. The mean rise in the bleeding time in patients who bled significantly to require surgical re-exploration (but did not receive platelets) was not significantly different from those who received platelets. These observations suggest that the administration of platelets has no clinical benefit in improving bleeding time following CPB.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...